

Dated : June 11, 2022

**BSE LIMITED**

Corporate Relations Department  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort  
Mumbai-400001  
Scrip code: 543264

**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**

Listing Department  
Exchange Plaza, 5th Floor, Plot no. C/1  
G Block, Bandra Kurla Complex, Bandra (E)  
Mumbai-400051  
Scrip Code: NURECA

**Sub: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the format specified under SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021, please find enclosed herewith, the disclosure of Related Party Transactions for the half-year ended March 31, 2022.

This is for your information and records.


**Yours faithfully,  
For Nureca Limited**



**(Chetna Anand)  
Company Secretary & Compliance Officer**

Encl. As above

										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.							
S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction (see Note 5)	Value of the related party transaction as approved by the audit committee (see Note 6a)	Value of transaction during the reporting period (see Note 6b)	In case monies are due to either party as a result of the transaction (see Note 1)		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments			
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost (see Note 7)	Tenure	Nature (loan/ advance/ inter corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured
1	Nureca Limited		Nureca Technologies Private Limited		Wholly Owned Subsidiary	Revenue from operations (net of returns)	N.A	0.06	-	-							
2	Nureca Limited		Nureca Technologies Private Limited		Wholly Owned Subsidiary	Reimbursement of expense paid by the Company	N.A	2.13	-	-							
3	Nureca Limited		Nectar Biopharma Private Limited		Entities in which KMP and/or their relatives have significant influence	Reimbursement of expense paid by the Company	Refer Note 1	7.06	-0.08	-1.47							
4	Nureca Limited		Nureca INC		Wholly Owned Subsidiary	Reimbursement of expense paid by the Company	N.A	0.49	0.15	0.64							
5	Nureca Limited		Nectar Biopharma Private Limited		Entities in which KMP and/or their relatives have significant influence	Expenses Incurred by Entity on Behalf of Company	Refer Note 1	0.91	-	-							
6	Nureca Limited		Mr. Saurabh Goyal		Managing Director	Managerial remuneration	Refer Note 1	7.76	-0.78	-0.68							
7	Nureca Limited		Mrs. Payal Goyal		Relatives of KMPs	Salary to KMPs and their relatives	Refer Note 1	5.70	-0.59	-0.58							
8	Nureca Limited		Mr. Aryan Goyal		Chief Executive Officer	Salary to KMPs and their relatives	Refer Note 1	2.13	-0.22	-0.00							
9	Nureca Limited		Mr. Gurvikram Singh		Company Secretary (Upto 10.11.2021)	Salary to KMPs and their relatives	Refer Note 1	0.05	-0.04	-							
10	Nureca Limited		Mr. Nishant Garg		Chief Financial Officer	Salary to KMPs and their relatives	Refer Note 1	1.30	-0.18	-0.18							
11	Nureca Limited		Ms. Chetna Anand		Company Secretary (w.e.f 11.11.2021)	Salary to KMPs and their relatives	Refer Note 1	0.50	-	-0.07							

For NURECA LIMITED  
  
 (NISHANT GARG)  
 Chief Financial Officer

12	Nureca Limited	Mr. Santosh Kumar Srivastava	Executive Director (upto 29.09.2021)	Salary to KMPs and their relatives	Refer Note 1	0.12	-	-											
13	Nureca Limited	Mr. Sushil Kumar Bhardwaj	Executive Director (w.e.f. 12.02.22 and upto 28.02.2022)	Salary to KMPs and their relatives	Refer Note 1	0.03	-	-											
14	Nureca Limited	Mr. Vijay Kumar Sharma	Independent Director	Sitting Fee	Refer Note 1	0.20	-	-											
15	Nureca Limited	Ms. Ruchita Agarwal	Independent Director	Sitting Fee	Refer Note 1	0.03	-	-											
16	Nureca Limited	Ms. Charu Singh	Independent Director	Sitting Fee	Refer Note 1	0.03	-	-											
17	Nureca Limited	Mr. Nitin Bidikar	Independent Director	Sitting Fee	Refer Note 1	0.02	-	-											
18	Nureca Limited	Mr. Vikram Chaudhery	Independent Director	Sitting Fee	Refer Note 1	0.02	-	-											
19	Nureca Limited	Nectar Biopharma Private Limited	Entities in which KMP and/or their relatives have significant influence	Commission and incentive	Refer Note 2	0.59	-	-											
20	Nureca Limited	Nectar Biopharma Private Limited	Entities in which KMP and/or their relatives have significant influence	Business support services	Refer Note 2	-0.56	-	-											
21	Nureca Limited	Nureca Healthcare Private Limited	Wholly Owned Subsidiary	Rent Income	N.A	0.01	-	-											
22	Nureca Limited	Nureca Technologies Private Limited	Wholly Owned Subsidiary	Rent Income	N.A	0.12	-	-											
23	Nureca Limited	Mrs. Raman Goyal	Relatives of KMPs	Rent Expenses	Refer Note 1	0.19	-	-											
24	Nureca Limited	Nectar Biopharma Private Limited	Entities in which KMP and/or their relatives have significant influence	Purchase of Fixed Asset	Refer Note 1	2.50	-	-											
25	Nureca Limited	Nureca INC	Wholly Owned Subsidiary	Investments in equity shares	N.A	-	0.46	0.46											
26	Nureca Limited	Nureca Healthcare Private Limited	Wholly Owned Subsidiary	Investments in equity shares	N.A	-	0.10	0.10											
27	Nureca Limited	Nureca Technologies Private Limited	Wholly Owned Subsidiary	Investments in equity shares	N.A	4.90	7.60	12.50									Investment (Right Issue)		Working capital requirement

Note 1 : Audit Committee approval has been received on all perpetual transactions for the term of reimbursement of expenses / purchase of fixed assets / managerial remuneration / salary to KMPs / sitting fees.

Note 2 : On 9 May 2020, the Company entered into an agreement with Nectar Biopharma Private Limited to facilitate the operations of the Company in accordance with the applicable laws in India, with effect from 23 May 2020 (i.e. the effective date of the scheme of arrangement) until such time that the Company is able to fulfil all legal formalities including but not limited to transfer of relevant licenses and obtaining requisite approvals from appropriate authorities.

For NURECA LIMITED  
  
(NISHANT GARG)  
Chief Financial Officer